Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 1:24 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 3,925 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Hypertension
Interventions: nitroglycerin, esmolol; Drug
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Pulmonary Arterial Hypertension
Interventions: treprostinil, Crono Five ambulatory pump; Drug · Device
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 3
States / cities: San Francisco, California • New York, New York • Oklahoma City, Oklahoma

Conditions: CVD
Interventions: Dietician electronic support; Behavioral
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years to 69 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Interventions: Renal Denervation (Symplicity Spyral™); Device
Lead sponsor: Medtronic Vascular; Industry
Eligibility: 18 Years and older
Enrollment: 1,899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 76
States / cities: Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 67 more

Conditions: Primary Open Angle Glaucoma
Interventions: Not listed
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Pulmonary Arterial Hypertension
Interventions: Hyperpolarized 13C-pyruvate; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 75 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Pulmonary Arterial Hypertension, Pulmonary Hypertension, Right Heart Dysfunction
Interventions: Aria CV Pulmonary Hypertension System; Device
Lead sponsor: Aria CV, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 12
States / cities: La Jolla, California • Los Angeles, California • Indianapolis, Indiana + 8 more

Conditions: Esophageal and Gastric Varices, Liver Cirrhosis
Interventions: Transjugular Intrahepatic Portosystemic Shunt (TIPS), Distal Splenorenal Shunt; Procedure
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2003
U.S. locations: 5
States / cities: Miami, Florida • Atlanta, Georgia • Cleveland, Ohio + 2 more

Conditions: Glaucoma, Primary Open Angle Glaucoma, Glaucoma, Suspect
Interventions: Collection of genetic material; Diagnostic Test
Lead sponsor: Duke University; Other
Eligibility: 40 Years to 90 Years
Enrollment: 1,152 participants
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Blood Pressure
Interventions: Intensive Clinic Management, Intensive Tailored Telehealth Management; Behavioral
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
Interventions: Direct Selective laser Trabeculoplasty; Device
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years and older
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Interventions: Qutenza (8% capsaicin); Drug
Lead sponsor: University of Rochester; Other
Eligibility: 15 Years to 80 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Hypertension, Aging
Interventions: Nicotinamide riboside, Placebo; Drug · Other
Lead sponsor: Douglas Seals; Other
Eligibility: 50 Years and older
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Boulder, Colorado

Conditions: Lung Diseases, Hypertension, Pulmonary
Interventions: Not listed
Lead sponsor: Vanderbilt University; Other
Eligibility: Up to 100 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2009
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: HTN-Hypertension, Blood Pressure Management
Interventions: CSN electrode was implanted around tissue including CSN branches; Device
Lead sponsor: Louis Stokes VA Medical Center; Federal
Eligibility: Not listed
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Glaucoma
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 30 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: High Blood Pressure, Kidney Disease, Chronic
Interventions: 3D Kidney model, Standard medical treatment; Behavioral
Lead sponsor: Hilary L Surratt, PhD; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Hypertension, Essential
Interventions: Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 23
States / cities: Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more

Conditions: Congenital Heart Disease, Pulmonary Hypertension
Interventions: Magnetic Resonance Imaging; Other
Lead sponsor: Stanford University; Other
Eligibility: Not listed
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Diabetes Mellitus, Type 2, Hypertension
Interventions: Canagliflozin, Placebo; Drug
Lead sponsor: Janssen Scientific Affairs, LLC; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 171 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 54
States / cities: Birmingham, Alabama • Gulf Shores, Alabama • Avondale, Arizona + 51 more

Conditions: Obstructive Sleep Apnea
Interventions: Inspiratory muscle strength training, Placebo; Other
Lead sponsor: University of Arizona; Other
Eligibility: 30 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Persistent Fetal Circulation Syndrome
Interventions: Milrinone Lactate; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: Up to 10 Days
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Detroit, Michigan • Philadelphia, Pennsylvania

Conditions: Hypertension
Interventions: optima4BP; Other
Lead sponsor: Optima Integrated Health; Industry
Eligibility: 21 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: San Francisco, California

Search by objective public record fields.

Esmolol or Nitroglycerin Infusion for Blood Pressure Control Prior to Cardiopulmonary Bypass (CPB) in Cardiac Surgery

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Safety, Efficacy, and Treatment Satisfaction Switching From Flolan to Remodulin Using the Crono Five Ambulatory Pump in Patients With PAH

e-Care for Heart Wellness

SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN

STudy to Assess Rapid Disease Progression by Clinical and Genetic Factors In Glaucoma patientS That Are High Risk

Metabolic Remodeling in Pulmonary Arterial Hypertension (PAH)

Treatment of Pulmonary Arterial Hypertension Using the Aria CV Pulmonary Hypertension System

Decompression Intervention of Variceal Rebleeding Trial (DIVERT)

Development and Validation of a Model to Predict Fast Progression in Glaucoma

Telehealth-Enhanced Assessment and Management

Direct vs Standard SLT for Glaucoma: A Noninferiority Trial

The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain

Nicotinamide Riboside for Treating Elevated Systolic Blood Pressure and Arterial Stiffness in Middle-aged and Older Adults

Genetic and Environmental Characteristics of Primary Pulmonary Hypertension

Direct Carotid Sinus Nerve Stimulation in Anesthetized Human Subjects

Aqueous Suppressant Versus Aqueous Outflow on Ocular Blood Flow

Health Literacy 3D Kidney Model Patient Education Trial

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

MRI and Computational Simulation Cardiology Study

Evaluation of Blood Pressure Reduction, Safety, and Tolerability of Canagliflozin in Patients With Hypertension and Type 2 Diabetes Mellitus on Stable Doses of Anti-hyperglycemic and Anti-hypertensive Agents

Inspiratory Muscle Strength Training for Sleep-related Breathing Disorders

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

Tailored Drug Titration Through Artificial Intelligence